Prognostic gene expression profiles are firmly established as an integral component of treatment planning for women with early-stage, estrogen receptor (ER)–positive,
ERBB2 (eg, formerly
HER2 or
HER2/neu)–negative breast cancer. Endorsement of these genomic biomarkers in treatment guidelines
1-3 and their widespread adoption in clinical practice
4,5 are the result of concerted efforts to establish the clinical validity and utility of these tests with retrospective
5-10 and prospective
11-15 validation studies. The most commonly ordered genomic assay for obtaining prognostic information on the risk of distant recurrence and for predicting the likelihood of benefit from adjuvant chemotherapy in women with ER-positive breast cancer is the 21-gene recurrence score (RS) on the Oncotype DX Breast Recurrence Score test.
4 The gene set included in the expression profile and the algorithm for determining the RS were developed using tumors from a subset of participants enrolled in the National Surgical Adjuvant Breast and Bowel Project B-20 trial
5,16 and from single-institution case series.
17 A key principle of biomarker development is that the cohorts used for discovery and validation should be representative of the populations targeted for clinical application of the biomarker.
18 The racial/ethnic distribution of the tumors used to develop the RS was not reported, but overall only 6% of B-20 participants were Black.
16 The landmark study
6 validating the prognostic accuracy of the RS in a subset of participants from the National Surgical Adjuvant Breast and Bowel Project B-14 trial included 5% Black women. Underrepresentation of women from racial/ethnic minority groups in the development and validation of the RS raises questions about the prognostic accuracy of the Oncotype DX Breast Recurrence Score test in populations other than non-Hispanic White people. This issue is especially relevant in light of persistent racial disparities in survival among Black women with ER-positive breast cancer.
19